Clinical failure among children with nonsevere community-acquired pneumonia treated with amoxicillin

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1451-1458

  Fontoura, Maria Socorro H ^a   Arajo Neto, César A ^a   Andrade, Sandra C S ^a   Brim, Rosa V ^a   Matutino, Adriana R ^a   Silva, Carolina C ^a   Santana, Milena C ^a   Nobre Bastos, Monalisa ^a   Oliveira, Felipe ^b   Barreto, Bruna B ^a   Santos, Pablo M ^a   Noblat, Lcia ^a   Cardoso, Maria Regina A ^c   Nascimento Carvalho, Cristiana M ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b Bahia Foundation for Science Development   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute respiratory infection; Amoxicillin; Lower respiratory tract disease; Lung disease; Outcome

Indexed keywords

AMOXICILLIN;

ABDOMINAL PAIN; ABNORMAL RESPIRATORY SOUND; ADVERSE OUTCOME; ARTICLE; ATELECTASIS; BREATHING DISORDER; CHILD; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; CRACKLES; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HYPERINFLATION; INFANT; LUNG EXAMINATION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PRESCHOOL CHILD; PROSPECTIVE STUDY; RADIODIAGNOSIS; RISK FACTOR; TACHYPNEA; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WHEEZING;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; INFANT; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 77952699641     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003777034     Document Type: Article

References (28)

1. McIntosh K. Current concepts: community-acquired pneumonia in children. N Engl J Med 2002;346:429-437
2. Benguigui Y, Stein F. Integrated management of childhood illness: an emphasis on the management of infectious diseases. Semin Pediatr Infect Dis 2006;17:80-98
3. McCracken GH Jr. Etiology and treatment of pneumonia. Pediatr Infect Dis J 2000;19:373-377
4. Shan F. The management of pneumonia in children in developing countries. Clin Infect Dis 1995;21(Suppl 3):S218-15
5. Nascimento-Carvalho CM, Lopes AA, Gomes MD, et al. The burden of pneumonia among children. J Trop Pediatr 2001;47:253-254
6. Grant GB, Campbell H, Dowell SF, et al. Recommendations for treatment of childhood non-severe pneumonia. Lancet Infect Dis 2009;9:185-196
7. Nascimento-Carvalho CM. Etiology of childhood community acquired pneumonia and its implications for vaccination. Braz J Infect Dis 2001;5:87-97
8. Nascimento-Carvalho CM. Pharmacotherapy of childhood pneumonia. Expert Opin Pharmacother 2010;11:225-231
9. Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther 2008;6:619-635
10. El-Radhi AS, Barry W. Thermometry in paediatric practice. Arch Dis Child 2006;91:351-356
11. World Health Organization. Integrated management of childhood illness chart booklet. WC 503.2. Geneva: WHO; 2008. Available from: http://whqlibdoc. who.int/publications/2008/ 9789241597289-eng.pdf [Last accessed 15 January 2009]
12. Nascimento-Carvalho CM, Souza-Marques HH. Recommendation of the Brazilian Society of Pediatrics for antibiotic therapy in children and adolescents with community-acquired pneumonia. Pan Am J Public Health 2004;15:380-387
13. Ayieko P, English M. Case management of childhood pneumonia in developing countries. Pediatr Infect Dis J 2007;26:432-440
14. Cherian T, Mulholland EK, Carlin JB, et al. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ 2005;83:353-359
15. Straus WL, Qazi SA, Kundi Z, et al. Antimicrobial resistance and clinical effectiveness of co-trimoxazole versus amoxicillin for pneumonia among children in Pakistan: randomized controlled trial. Pakistan Co-trimoxazole Study Group. Lancet 1998;352:270-274
16. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002;360:835-841
17. Agarwal G, Awasthi S, Kabra SK, et al. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled Trial. BMJ 2004;328:791-796
18. Hazir T, Qazi SA, Bin Nisar Y, et al. Comparison of standard versus double dose of amoxicillin in the treatment of non-severe pneumonia in children aged 2 -- 59 months: a multi-centre, double blind, randomised controlled trial in Pakistan. Arch Dis Child 2007;92:291-297
19. Awasthi S, Agarwal G, Singh JV, et al. Effectiveness of 3-day amoxycillin vs 5-day co-trimoxazole in the treatment of non-severe pneumonia in children aged 2 -- 59 months of age: a multi-centric open labeled trial. J Trop Pediatr 2008;54:382-389
20. Awasthi S, Agarwal G, Kabra SK, et al. Does 3-day course of oral amoxycillin benefit children of non-severe pneumonia with wheeze: a multicentric randomised controlled trial. PLoS One 2008;3:e1991
21. Korppi M. Community-acquired pneumonia in children: issues in optimizing antibacterial treatment. Paediatr Drugs 2003;5:821-832
22. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Shortversus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis. Drugs 2008;68:1841-1854
23. Haider BA, Saeed MA, Bhutta ZA. Short-course versus long-course antibiotic therapy for non-severe communityacquired pneumonia in children aged 2 months to 59 months. Cochrane Databse Syst Rev 2008;2:CD005976
24. Council for International Organisations of Medical Sciences. Current challenges in pharmacovigilance: pragmatic approaches: report of CIOMS working group V. Geneva: CIOMS; 2001
25. Virkki R, Juven T, Mertsola J, Ruuskanen O. Radiographic follow-up of pneumonia in children. Pediatr Pulmonol 2005;40:223-227
26. Nascimento-Carvalho CM, Ribeiro CT, Cardoso MR, et al. The role of respiratory viral infections among children hospitalized for community-acquired pneumonia in a developing country. Pediatr Infect Dis 2008;27:939-941
27. Wolkers PC, Mantese OC, de Paula A, et al. New susceptibility breakpoints in antimicrobial resistance rates of invasive pneumococcal strains. J Pediatr (Rio J) 2009;85:421-425
28. Pichichero ME, Reed MD. Variations in amoxicillin pharmacokinetic/ pharmacodynamic parameters may explain treatment failures in acute otitis media. Paediatr Drugs 2009;11:243-249